X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New PhRMA report: More than 170 medicines in development for diabetes offer patients longer, healthier lives

By Hannah Mooney  |    November 14, 2016
Today, there are more than 30 million Americans suffering from type 1 or type 2 diabetes. Roughly 5 percent of patients have type 1 and 90 to 95 percent suffer from type 2, highlighting the...   Read More

New report highlights need to speed patent examination

By Mark Grayson  |    November 2, 2016
The Center for the Protection of Intellectual Property released a new report, “The Long Wait for Innovation: The Global Patent Pendency Problem,” documenting the growing global challenge of patent...   Read More

Study highlights negative impact of Canada's promise doctrine on R and D investment

By Mark Grayson  |    October 21, 2016
A newly published study from Charles River Associates (CRA) has found that Canada’s approach to intellectual property (IP), innovation and patient care is being jeopardized because of its adoption...   Read More

New report highlights impact of intellectual property on U.S. economy

By Mark Grayson  |    October 13, 2016
In late September, the U.S. Department of Commerce released a comprehensive report that found intellectual property (IP) intensive industries contribute more than $6 trillion (38.2 percent) to...   Read More

4 recommendations for ICER

By Lauren Neves  |    September 26, 2016
For years, PhRMA has supported policies that ensure health care decisions are grounded in the best available evidence. In our policy solutions for delivering innovative treatments to patients...   Read More

2016 BCI Survey: A pro-innovation environment is essential for biopharmaceutical investment

By Guest Contributor  |    September 16, 2016
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

New PhRMA report: New medicines in development for autoimmune diseases offer patients hope for brighter futures

By Hannah Mooney  |    September 12, 2016
Currently, more than 23.5 million Americans are affected by one of the more than 80 autoimmune diseases identified to date. These diseases range in severity, with their own characteristics and...   Read More

Patients showcase longer, healthier lives in new “From Hope to Cures” ads

By Ieva M. Augstums  |    September 6, 2016
For Ed, a longer life meant more time with family, friends and his dog, BearBear. When he was diagnosed with colon cancer, he underwent six weeks of radiation, seven months of chemotherapy and 10...   Read More

Fact Check Friday: The truth about biopharmaceutical patents

By Mark Grayson  |    August 26, 2016
MYTH: Biopharmaceutical companies use government-protected monopolies to raise costs on medicines. FACT: Patent-protected medicines routinely face competition from other brand name medicines,...   Read More

Working together to combat global Zika threat

By Emma Van Hook  |    August 4, 2016
The Zika virus is top of mind as the 2016 Summer Olympic Games get underway tomorrow in Rio. While once thought to be confined to limited areas of Africa, Southeast Asia and the Pacific Islands,...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates